» Articles » PMID: 3040158

Oestrogen Receptor Activity in Intraduct and Invasive Breast Carcinomas

Overview
Specialty Oncology
Date 1987 Jan 1
PMID 3040158
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Breast cancers analysed for oestrogen receptor activity over a ten-year period have been surveyed in order to select a group of intraduct carcinomas without invasion and a second, control group of invasive carcinomas without intraduct carcinoma. Examination of histological sections taken from the face of the tumour samples used for receptor analysis showed only 13 purely intraduct carcinomas without any invasion. Each of these was matched for age, menstrual status, hospital of origin, and approximate assay date with two purely invasive ductal carcinomas of no specialized type (26 invasive carcinomas in all). In invasive carcinomas, a significantly higher proportion of the specimen was occupied by malignant cells (mean 30%) than in the intraduct carcinomas (mean 15%), and receptors were detected more frequently (77% versus 46%) and at higher concentrations (mean 26 times on a wet weight basis, 19 times on a protein basis). When allowance was made for the difference in cellularity between the groups, the invasive carcinomas still contained significantly higher concentrations of receptor protein (mean = ten times more on a wet weight basis). These findings suggest that the expression of the gene encoding the receptor protein tends to be a property either maintained, or acquired upon progression to invasive disease. Further studies will be needed to determine whether or not the established prognostic and predictive values of receptor measurements apply to non-invasive disease, and to clarify the relationship between receptor expression in benign and malignant breast in relation to morphological changes.

Citing Articles

William L. McGuire Memorial Symposium. Estrogen and progestin effects in human breast carcinogenesis.

King R Breast Cancer Res Treat. 1993; 27(1-2):3-15.

PMID: 8260728 DOI: 10.1007/BF00683189.


Prevalence of aneuploidy, overexpressed ER, and overexpressed EGFR in random breast aspirates of women at high and low risk for breast cancer.

Fabian C, Zalles C, Kamel S, Kimler B, McKittrick R, Tranin A Breast Cancer Res Treat. 1994; 30(3):263-74.

PMID: 7981444 DOI: 10.1007/BF00665967.


Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy.

Archer S, Eliopoulos A, Spandidos D, Barnes D, Ellis I, Blamey R Br J Cancer. 1995; 72(5):1259-66.

PMID: 7577479 PMC: 2033919. DOI: 10.1038/bjc.1995.497.


Oestrogen receptor activity in breast cancer detected at a prevalence screening examination.

Roberts M, Hawkins R, Alexander F, Anderson T, Steele R Breast Cancer Res Treat. 1987; 10(3):267-72.

PMID: 3447645 DOI: 10.1007/BF01805763.


Immunohistochemical study of D5 antigen (an oestrogen receptor related protein) in normal breast, benign breast disease, and mammary carcinoma in situ.

Girling A, Caleffi M, King R, Millis R J Clin Pathol. 1988; 41(4):448-53.

PMID: 2835402 PMC: 1141474. DOI: 10.1136/jcp.41.4.448.


References
1.
Cuzick J, Wang D, Bulbrook R . The prevention of breast cancer. Lancet. 1986; 1(8472):83-6. DOI: 10.1016/s0140-6736(86)90729-4. View

2.
Fisher E, Osborne C, McGuire W, Redmond C, Knight 3rd W, Fisher B . Correlation of primary breast cancer histopathology and estrogen receptor content. Breast Cancer Res Treat. 1981; 1(1):37-41. DOI: 10.1007/BF01807890. View

3.
McCarty Jr K, Miller L, Cox E, Konrath J, McCarty Sr K . Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med. 1985; 109(8):716-21. View

4.
Bishop J . Steroid receptors: oncogenes as hormone receptors. Nature. 1986; 321(6066):112-3. DOI: 10.1038/321112a0. View

5.
Israel L, Band P . Hormones as cancer growth factors. Lancet. 1984; 2(8407):843-4. DOI: 10.1016/s0140-6736(84)90876-6. View